Fozivudine: BM 211290, fozivudine tidoxil, FZT, HDP 990002, W 09726867.
Fozivudine [BM 211290, fozivudine tidoxil, FZT, HDP 990002, W 09726867] is a thioether lipid conjugate of zidovudine (AZT) in clinical development with Heidelberg Pharma Holdings for the potential treatment of HIV infection. Heidelberg Pharma's proprietary Linker-Cleavag-Enzyme Technology (LCE_Technology) is used to conjugate specific carriers to parent compounds, significantly improving their pharmacological, toxicological and/or clinical profile. LCE_Technology was originated at Boehringer Mannheim, which was acquired by, and integrated into, Roche. In 1999, when Heidelberg Pharma was founded, following a management buy-out from Roche Diagnostics GmbH, the new company acquired full ownership of the intellectual property and documentation related to various proprietary compounds, the LCE_Technology and its applications. According to Heidelberg Pharma's pipeline, published in August 2003, the product candidate, HDP 99.0002 (the company-specific code for fozivudine) will be in phase III development until early 2006, at which time the company hopes to file an NDA. A phase II study of fozivudine in 72 antiretroviral-naive patients with HIV infection was completed in the US and France by Roche.
D000818:Animals; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008055:Lipids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015215:Zidovudine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D008055:Lipids; D015215:Zidovudine; C408972:fozivudine tidoxil